Page 48 - Research Models News Today : Breaking News, Live Updates & Top Stories | Vimarsana

StockNews.com assumed coverage on shares of Charles River Laboratories International (NYSE:CRL – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the medical research company’s stock. A number of other brokerages have also recently commented on CRL. Guggenheim raised Charles River Laboratories International from a […]

Mitchell & Pahl Private Wealth LLC raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 8.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,231 shares of the medical research company’s stock after purchasing an additional […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $190.39, for a total transaction of $65,684.55. Following the sale, the executive vice president now directly owns 24,026 shares […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) – Stock analysts at William Blair reduced their Q4 2023 earnings estimates for Charles River Laboratories International in a research report issued on Friday, May 12th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings of $2.46 per share for […]

Impax Asset Management Group plc purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) during the fourth quarter, HoldingsChannel reports. The firm purchased 2,155 shares of the medical research company’s stock, valued at approximately $470,000. Several other hedge funds and other institutional investors have also bought and sold […]